Cita APA (7a ed.)
Luo, Q., Zhang, L., Hao, Y., Xu, C., Wang, X., Jia, Z., . . . Yin, Y. (2025). Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4. Breast Cancer Research, 27(1), 1-18.
Cita Chicago Style (17a ed.)
Luo, Qing, et al. "Erdafitinib Inhibits the Tumorigenicity of MDA-MB-231 Triple-negative Breast Cancer Cells by Inducing TRIM25/ubiquitin-dependent Degradation of FGFR4." Breast Cancer Research 27, no. 1 (2025): 1-18.
Cita MLA (9a ed.)
Luo, Qing, et al. "Erdafitinib Inhibits the Tumorigenicity of MDA-MB-231 Triple-negative Breast Cancer Cells by Inducing TRIM25/ubiquitin-dependent Degradation of FGFR4." Breast Cancer Research, vol. 27, no. 1, 2025, pp. 1-18.
Precaución: Estas citas no son 100% exactas.